Information Provided By:
Fly News Breaks for October 17, 2019
ALXN
Oct 17, 2019 | 06:58 EDT
BofA/Merrill analyst Geoff Meacham reinstated coverage of Alexion Pharmaceuticals with a Buy rating and $130 price target. "Noise" around complement competition has overshadowed Alexion's "strong" fundamentals, driven by its Soliris/Ultomiris franchise, Meacham tells investors in a research note. The analyst likes the stock's risk/reward profile given the company's "differentiated" growth and "discounted" valuation.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.